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Abstract
Retinoblastoma (RB) is a pediatric retinal tumor that overexpresses the ganglioside GD2. 
Although it is treatable in patients with early diagnosis, patients may lose one or two eyes. We 
generated GD2-specific chimeric antigen receptor T lymphocytes (GD2.CAR-Ts) and locally 
delivered them to mice with an in-situ grafting RB. When used in combination with the local 
release of interleukin (IL)-15 and an injectable hydrogel, we showed that GD2.CAR-Ts 
successfully eliminate RB tumor cells without impairment of the mouse vision.
Introduction
RB is a pediatric cancer developed within the retina that occurs in both heritable form in 
association with germ-line RB1 gene (encodes RB transcriptional corepressor 1) mutation or 
more frequently in nonheritable form1. When RB is confined to the eye, cryotherapy, 
thermotherapy, chemotherapy and radiotherapy are used, but enucleation, with consequent 
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loss of vision, is frequently the best option for advanced stages2,3. Development of treatment 
strategies that can eradicate the tumor, but preserve the vision would significantly enhance 
the quality of life of RB patients. Immunotherapy in the form of adoptive transfer of CAR-
Ts is perceived as the most promising therapy for pediatric patients with acute lymphoblastic 
leukemia4. Here we have developed a local immunotherapy approach based on GD2-specific 
CAR-Ts releasing IL-15 and encapsulated in in-situ formed injectable chitosan hydrogel that 
allows tumor eradication whilst preserving the vision.
RB like other neuroepithelial cancer expresses the ganglioside GD25. GD2 has been targeted 
in pediatric patients with neuroblastoma (NB) via either monoclonal antibodies or more 
recently CAR-Ts6,7. In particular, GD2-specific CAR-Ts (GD2.CAR-Ts) have been well 
tolerated and produced clinical benefits in some patients with NB6. We evaluated GD2 
expression in human RB specimens. GD2 was expressed on the human RB, but not on the 
normal human retina (Figure 1A). GD2 was also found highly expressed in the two RB cell 
lines Y79 and WERI-rb-1 (Figure 1B). We then investigated whether GD2.CAR-Ts can 
target RB cancer cells by co-culturing CAR-Ts with RB tumor cell lines. Both control 
CD19-specific CAR (CD19.CAR) and GD2.CAR were expressed in transduced T cells 
(Extended Data Figure 1A), but only GD2.CAR-Ts specifically eliminated both Y79 and 
WERI-rb-1 RB cells (Figure 1C). The antitumor activity of GD2.CAR-Ts was corroborated 
by the detection of Th1 cytokines (IFN-γ and IL-2) in culture supernatants as well as by 
their proliferation in response to RB tumor cells (Extended Data Figure 1B).
Result
To evaluate the antitumor effects of GD2.CAR-Ts in vivo, we used in an in-situ xenograft 
nude mice model as previously described8. In this model, RB tumor cells are implanted in 
the subretinal space, creating a tumor that mimic the human disease, which better 
recapitulates the origin of human RB as compared to intravitreal inoculation. We stably 
expressed (via retroviral vector) the enhanced green fluorescence protein (eGFP)-firefly 
luciferase (FFLuc) in the Y79 RB cell line and engrafted 104 cells via subretinal injection. 
Seven days post-grafting, GD2.CAR-Ts or CD19.CAR-Ts (106 cells) were inoculated 
intratumor, via subretinal injection. GD2.CAR-Ts promoted delayed tumor growth measured 
by either bioluminescence (BLI) or direct tumor measurement (Figures 1D, 1E, and 1G), but 
did not produce tumor eradication as all mice developed tumor and required euthanasia by 
day 70 (Figures 1F, 1G). Overall, these data suggest that local injection of GD2.CAR-Ts can 
transiently control RB growth.
In the attempt to eradicate the tumor, we hypothesized that providing GD2.CAR-Ts with self 
growth factor support would enhance their therapeutic effect by prolonging their persistence 
within the tumor. We introduced IL-15, an immune-enhancing cytokine known to promote T 
cell proliferation, activation, and survival9 into the GD2.CAR construct10 (Extended Data 
Figure 1A). While the addition of IL-15 did not cause RB regression in mice treated with 
CD19.CAR-Ts, GD2.CAR-Ts releasing IL-15 (GD2.CAR.15) showed significantly 
improved antitumor effects with 60% treated mice remaining tumor free up to day 70 
(Figure 2A-E) (p=0.0010). These data indicate that IL-15 by sustaining the local survival of 
GD2.CAR-Ts enhances their antitumor effects.
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Intratumor delivery of T cells occurs as a single “all-at-once” delivery and it does not 
provide the extended time of intralesional persistence of CAR-Ts required to sustain 
antitumor effects. A delivery vehicle promoting CAR-T cell persistence would be highly 
preferred. In-situ formed injectable hydrogels allow localized and sustained cell 
delivery11-13. We selected the chitosan-polyethylene glycol (PEG) thermosensitive hydrogel 
forming gel at physiologic temperature studied as optimal injectable hydrogels to deliver 
CAR-Ts within the eye (Extended Data Figures 2 and 3). The majority of T cells 
encapsulated within the hydrogel remained viable, were released from the gel within one 
week in vitro and retained their cytotoxic activity (Extended Data Figure 4). We next tested 
if the encapsulated GD2.CAR.15-Ts would eradicate RB. The chitosan-PEG hydrogel 
significantly improved the antitumor effects of GD2.CAR-Ts (Figure 3A, P = 0.0024, n = 
15), but the combination of GD2.CAR.15-Ts and chitosan-PEG hydrogel completely 
controlled the tumor growth and prevented tumor recurrence (p <0.0001, n = 15) (Figure 3B-
D). Histological study confirmed that the combination of injectable hydrogel and 
GD2.CAR-Ts or GD2.CAR.15-Ts not only allowed tumor clearance, but also improved 
structural recovery of the retina (Figure 3E). Analysis of the dissected posterior segments at 
day 60 post-treatment showed the presence of GD2.CAR-Ts in mice engrafted combining 
hydrogel and GD2.CAR-Ts secreting IL-15 (Figures 4A and 4B). The retinal structure was 
essentially preserved, even if signs of inflammatory response and a cavity corresponding to 
the eliminated tumor were observed (Figure 4C). In addition, the hydrogel facilitated T cell 
migration and further improved their viability. Western blotting of the lysates obtained from 
the eye of treated mice further revealed that the hydrogel increased IL-15 detection within 
the eye. This effect can be due to both enhanced persistence of the T cells and increased 
retention of IL-15 within the eye (Extended Data Figures 5A and 5B). Overall these data 
support the conclusion that the local co-injection of the chitosan-PEG thermosensitive 
hydrogel and GD2.CAR.15-Ts eradicate RB.
To further evaluate if the proposed local immunotherapy preserves the retina function, we 
performed Fundoscopy, optical coherent tomography (OCT), or Electroretinography (ERG) 
analysis. The fundus imaging revealed morphological changes under the retina after tumor 
engrafting and treatment8. After Y79-eGFP-FFLuc tumor cell engraftment, the GFP signal 
was clearly detectable in control mice, but absent in mice treated with the combination of 
hydrogel and GD2.CAR-Ts secreting IL-15, without evidences of macroscopic damages of 
the retina (Figure 5A). ERG performed to test the retinal response to light showed loss of 
retinal response to the light in tumor bearing mice as decrease in both scotopic a and b 
waves and photopic b wave (Figure 5B). In contrast, in mice treated with the combination of 
hydrogel and GD2.CAR.15-Ts the retinal function was significantly improved (p = 0.009, n 
= 7) (Figure 5B).
Discussion
Here we propose the local immunotherapy approach that combines effector T cells targeting 
GD2, the T cell growth factor IL-15 and chitosan-PEG injectable hydrogel to eradicate RB 
in a preclinical model. GD2 is a marker on the neuroepithelia tumors and GD2-specific 
antibodies and CARs have been developed6, 7, 14. However, no attempt has been so far 
reported to target GD2 in RB. GD2.CAR-Ts showed potent cytotoxic activity against RB 
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tumor cell lines in vitro. However, GD2.CAR-Ts eradicated the RB in vivo only upon the 
incorporation of IL-15 and encapsulation within the chitosan-PEG injectable hydrogel, 
which improve T cell lifespan and biodistribution, respectively. While we previously 
reported the critical role of IL-15 expressed by CAR-Ts in prolonging their survival and 
antitumor activity in metastatic tumor models10, 15, we report here the critical role of a 
biomaterial scaffold in supporting the antitumor effect of CAR-Ts when injected intratumor.
The chitosan-based injectable hydrogels are biocompatible and biodegradable13, 16, 17. 
Previous study using chitosan-PEG hydrogel demonstrated its positive effects on cell 
delivery due to its low viscosity13, 18. The in-situ gelation we propose facilitates CAR-T cell 
movements and confines IL-15 within the hydrogel, thus facilitating the use of the cytokine 
by the CAR-Ts and limiting its diffusion. Remarkably, the immunotherapy approach we 
propose preserves retinal function. While activated T cells may cause toxicity in the retina, 
the injectable hydrogel reduced inflammation and retinal detachment by localized delivery 
of T cells. The proposed approach has potential clinical translation since GD2.CAR-Ts and 
GD2.CAR-natural killer T cells releasing IL-15 are currently in clinical trials in patients 
with neuroblastoma (NCT03721068 and NCT03294954), although the safety of intra-
tumoral injection will be further evaluated in a future study of retinoblastoma immune 
therapy. Furthermore, the injectable chitosan-PEG hydrogel can be generated following 
good laboratory practice or good manufacture practice11, 16.
METHODS
Synthesis and characterization of injectable of hydrogels
The chitosan-PEG hydrogel was synthesized adopting from previous study17,19. 0.2 g PEG 
and 0.2 g N-hydroxysuccinimide (NHS) were dissolved in 5 mL of DMSO and reacted for 
72 hours at room temperature. The solvent was then removed using evaporation. Thereafter, 
chitosan was dissolved in 2% w/v acetic acid aqueous solution to prepare solution at 2% w/v 
concentration. Reaction product (NHS-PEG-NHS) was mixed with 2% w/v chitosan 
solution. The reaction was carried out for 24 hours and product was purified via centrifugal 
ultrafiltration (10 kDa cut-off molecular weight) against DI H2O. Finally, the product was 
mixed with β-glycerophosphate solution to finalize hydrogel precursor for injection. The 
alginate hydrogel synthesis followed our previous study20. Briefly, 5 mL of 2% alginate 
aqueous solution was mixed with 5 mL of 2% gelatin aqueous solution in 20 mL vial. Next, 
40 mg (1-ethyl-3-(3-dimethylaminopropyl) carbodiimide and 30 mg NHS were added and 
reacted at ambient temperature for 24 hours. The hydrogel precursor was mixed with the 
same volume of 0.05 M CaCl2 solution spontaneously to finish crosslinking. The structure 
of hydrogel was characterized with 1H NMR spectroscopy (600 MHz INova spectrometer, 
D2O solvent), and the morphology was observed by scanning electron microscopy (Zeiss 
Supra 25). The rheological test was performed on using TA instrument discovery HR-1 
rheometer with 20 mm diameter parallel plate at ambient and physiological temperature. 
Linear viscoelastic region was determined by performing a strain sweep from 0.1 to 10% 
strain at 1Hz oscillation frequency. The storage and loss modulus were calculated using 
linear range (0 - 5% strain) average.
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Cell culture, production CAR-Ts and functional assays
All cell lines (Y79 and WERI-rb-1) used in this study were purchased from American Type 
Culture Collection. Y79 and WERI-rb-1 cell lines were cultured in RPMI 1640 media 
supplied with 10% FBS, and 1% Glutamax. Generation of GD2.CAR-Ts and GD2.CAR.15-
Ts followed the same procedure as previously described10. Briefly, peripheral blood 
nononuclear cells (PBMCs) were isolated from buffy coats (Gulf Coast Regional Blood 
Center) using Lymphoprep (Accurate Chemical and Scientific Corporation). PBMCs were 
then activated using 1 mg/mL immobilized CD3 (Miltenyi Biotec) and CD28 (BD 
Biosciences) antibodies. After 3 days, cells were transduced with retroviral supernatants and 
expanded in complete medium supplemented with IL-7 (10 ng/mL, PeproTech) and IL-15 (5 
ng/mL, PeproTech) and expanded by feeding them every 3 to 4 days with fresh complete 
media and cytokines21, 22, and expression of CAR was analyzed following previous 
procedure10. Tumor cell immunophenotyping followed the previous procedure10. Briefly, 
the Y79 and WERI-RB-1 cells were harvested and washed with FACS Buffer. Next, the 
tumor cells were incubated with anti-GD2 antibody (BD bioscience, clone 14.g2a) and 
isotype for 30 minutes 4°C in the dark. Last, the cells were washed with FACs buffer and 
suspended in FACs buffer for FACS analysis on a BD LSRFortessa cell analyzer with 
FACSDiva software. FACS data were processed on FCSexpress 6 software. The gating 
strategy is shown in extended data Figure 6A. Isotype was used to gate negative samples. 
The staining methods was described previously, anti-CD3-APC, anti-CD4-FITC, anti-CD8-
PE, anti-CD45-BV510, anti-GD2-BV711 antibodies were used. The counting beads (Count 
Bright, Invitrogen) were added following the manufacturer's instructions.
T cell release from the hydrogel and functional activity
The alginate and chitosan hydrogels were encapsulated with 0.2 mL volume with 1 x 106, 4 
x 106, and 1 x 107 T cells. The hydrogel was formed in 6-well transwell plate with culture 
media. Cell counting and cell viability using trypan blue were performed daily. To measure 
the antitumor activity of CAR-Ts released from the hydrogel 2.5 x 105 Y79 or WERI-RB-1 
cells were seeded on 24-well plate prior to add hydrogel. T cells were encapsulated with 
alginate-gelatin and chitosan-PEG hydrogels in 0.2 mL volume with 0.5 x 105 or 2.5 x 105 T 
cells prior to transfer to each well. Blank hydrogel and T cells without hydrogel were used 
as control groups. After coculture for 72 hours, tumor cells were imaged by fluorescence 
microscope and enumerated by flow cytometry. Cytokines (IL-2 and IFN-γ) released by 
CAR-Ts upon targeting tumor cells were measured in the coculture supernatant collected 
after 24 hours using specific enzyme-linked immunosorbent assays (R&D systems, Inc,).
In vivo studies
Animal experiments were conducted in accordance with the policies of the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill. Male 
and female 6- to 8- week old NU/NU nude mice were purchased from the Charles River 
Laboratory. Ketamine (100 mg/kg)/Xylazine (10 mg/kg) injected intraperitoneally or 
inhalation of 2.5% isoflurane were used for anesthesia. To establish the xenograft RB model, 
1 x 104 tumor cells suspended in a final volume of in 1 uL were injected under the retina8. 
Seven days later, 1 x 106 CAR-Ts in phosphate buffered saline (PBS) or encapsulated in 1 
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uL hydrogel were also injected under the retina. Blank hydrogels were also used as controls. 
Tumor growth was monitored by BLI using Caliper IVIS imaging system. Mice were 
infused with 150 mg/kg body D-Luciferin 10 min prior to imaging. The exposure time was 1 
or 5 minutes, and BLI was determined using Living Image software. Mice were euthanized 
when tumor invaded the cornea or tumor volume exceed 500 mm3. The photographs of mice 
were shown in extended data Figure 6B.
Fundus and OCT
Mice were anesthetized and pupils dilated with 1% tropicamide. Fundus images were 
captured using a Micron IV retinal imaging system (Phoenix Research Labs). Corneas were 
moistened with Genteal lubricant eye gel (Novartis) and positioned with the Micron 
eyepiece in direct contact with the eye through the gel. OCT images were captured using the 
full-scan setting as an average of 10 frames/scan.
Electroretinography (ERG)
ERG was recorded and analyzed according to previously published protocols23. Briefly, 
mice were dark-adapted overnight, and eyes were dilated with 1% tropicamide under dim 
red light. Genteal was applied to each eye, and recordings were made using gold electrodes 
that were placed on the cornea. The reference electrode was inserted subcutaneously behind 
the head, and the ground electrode in the tail. ERG was collected using an Espion E2 system 
(Diagnosys), and mice body temperature was maintained at 37°C during the experiment.
T cell migration and IL-15 retention assay
The migration of GD2.CAR.15 CAR-Ts was measured by placing 106 T cells in chitosan-
PEG hydrogel or PBS into a three-dimensional collagen gel (2 mg/mL, Sigma) in complete 
medium24. T cells migrated through the collagen gel boundary were stained with LIVE/
DEAD viability kits (Invitrogen) and imaged with fluorescence microscopy. The migration 
distance was measured using ImageJ software.
Histology sectioning, immunohistochemistry, and western blotting.
Human RB tumors were frozen in optimal cutting temperature compound and serially 
sectioned (10 μm). Slides were fixed with 4% PFA for 10 minutes (−20°C) and 
immunohistochemical analyses were performed. RB tumors were detected with anti-GD2 (1: 
400, MilliporeSigma) antibody. Alexa Fluor 488 anti-mouse (Life Technologies) were used 
as secondary antibodies respectively (1:500). Omission of the primary antibody was used as 
a negative control for nonspecific binding. Cell nuclei were stained for 10 minutes with 
4′,6′-diamidino-2-phenylindole (DAPI, 1: 5,000) for confocal microscopy. Mice were 
randomly selected from each cohort and sacrificed for histology and western blotting 
analysis 35 days post treatment. The haemotoxylin and eosin (H&E) staining of eye tissues 
were carried out by the UNC Center for Gastrointestinal Biology and Disease Histology 
Core Facility. Briefly, fixed tissues were embedded in paraffin and sectioned into 10-mm 
sections for eye tissues. Sections were stained with H&E according to conventional staining 
protocols and visualized using conventional bright-field microscopy. Mouse eyes were 
dissected. Lysate obtained from the dissected eye were used for western blotting. Lysates 
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were loaded in sample buffer and separated using 4-20% SDS-PAGE gels (Bio-Rad). Blots 
were transferred, stained (anti-IL-15 antibody, ProSci 1:500), and imaged according to the 
manufacturer's (Bio-Rad) instructions.
Statistics and reproducibility
All quantitative data were expressed as the mean and standard deviation. The size of animal 
samples was calculated based on GPower7.1 software and logistic limitations, animals were 
randomly allocated into different groups. All the studies are sufficiently powered to yield 
statistically significant results (95% confidence interval). The data were analyzed by one-
way or two-way analysis of variance (ANOVA), and a p-value less than 0.05 was considered 
significant. Survival curves were plotted using the Kaplan-Meier method, and the differences 
in the survival between groups were assessed by log-rank test.
Reporting Summary
Further information on research design is available in the Nature Research Reporting 
Summary linked to this article.
Extended Data
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Extended Data Fig. 1. T cells expressed CAR and effector-tumor coculture exhibited elevated 
cytokine release
(A) CAR expression in T cells transduced with retroviral vectors encoding GD2.CAR, 
CD19.CAR, GD2.CAR.IL15, and CD19.CAR.IL15. CAR expression was evaluated by flow 
cytometry. (B) IL-2 and IFN-γ released in the culture supernatants of CAR-Ts co-cultured 
with tumor cells. Supernatant was collected at 24 hours and cytokines were measured by 
specific ELISA (E:T=1:5, n = 5 donor/group, E:T=1:2, n = 3 donor/group). Data presented 
show mean and SEM.
Extended Data Fig. 2. The morphologic and rheologic properties of Chitosan-PEG hydrogel
(A) Lyophilized injectable hydrogel was imaged by scanning electron microscopy. The 
image showed 63 um average pore diameter of the hydrogel (n=10 technical replicates). (B) 
GD2.CAR-Ts labelled with eGFP-FFLuc were encapsulated into the hydrogel and 
visualized by florescence macroscopy (B). Assessment of the viscoelastic properties of the 
injectable hydrogel tested at 23°C and 37°C (n=10 technical replicates) (C). Rheological test 
result of the chitosan-PEG injectable hydrogel and water/saline16 (n=10 technical 
replicates). Data presented show mean and SD.
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Extended Data Fig. 3. Molecular characterization of chitosan-PEG hydrogel
(A)1H NMR spectra of the chitosan and the chitosan-PEG hydrogel precursor and (B) 
molecular weight of Chitosan-PEG precursors measured by dynamics light scattering (n=12 
technical replicates). Data presented show mean and SD.
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Extended Data Fig. 4. CAR-Ts release from hydrogels and chitosan-PEG hydrogel encapsulated 
GD2.CAR-Ts effectively eliminated tumor
(A) Viability of CAR-Ts released from alginate-gelatin and chitosan-PEG injectable 
hydrogel (n =3 donor/group). (B) CAR-T cell release Profile from alginate-gelatin and 
chitosan-PEG injectable hydrogel (n =3 donors/group). RB tumor cell lines were co-cultured 
with GD2.CAR-Ts or CD19.CAR-Ts at the effector to tumor ratio of 1:1 (C) and 1:5 (D) for 
7 days upon encapsulation with the hydrogels. All cells were collected and analyzed by flow 
cytometry to enumerate T cells and residual tumor cells in the culture (n =3 donors/group). 
Data presented show mean and SEM.
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Extended Data Fig. 5. The hydrogel facilitates the antitumor activity of GD2.CAR-Ts.
(A) Migration assay showing T cell migration and viability in the collagen gel (Fluorescence 
Green: Living cells, Red: Dead cells) on days 1 and 4. 24 (B) Western blotting analysis of the 
protein lysate of the dissected eyes at day 35 post-treatment to detect IL-15. The statistical 
significance was determined using one-way ANOVA with Tukey’s post hoc test 
(GD2.CAR.15 versus GD2.CAR.15 hydrogel) P=0.012. n=3 individual sample/group. Data 
presented as mean and SEM.
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Extended Data Fig. 6. The Gating strategy and photography of mice
(A) Gating strategy to assess effector-tumor coculture (CD4+/CD8+ cells) and the presence 
of T cells (CD45+ cells) and RB tumor cells (GD2+ cells) in the posterior segment of the 
eye by flow cytometry. (B) Photographs of representative nu/nu mice (n=15/group) 35 days 
after engraftment with the Y79-eGFP-FFLuc tumor cell line and receiving the indicated 
treatments.
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Figure 1. Retinoblastoma express GD2 on the cell surface, and GD2.CAR-Ts control the growth 
of RB, but fail to prevent tumor recurrence
(A) Representative human RB section stained with the GD2-AlexaFluor488 Antibody 
showed extensive expression of GD2 on the tumor surface, while normal retina was used as 
negative control where GD2 is absent (Representative of n = 3 individual repeated 
experiments). (B) Representative immunophenotyping result of Y79 and WERI-rb-1 human 
RB cell lines revealed expression of GD2 (Y79 and WERI-rb-1, representative of n = 3 
individual experiments per group). (C) RB tumor cell lines were co-cultured with 
GD2.CAR-Ts and CD19.CAR-Ts at the tumor to T cell ratio of 1:1. All the cells were 
collected and analyzed by FACS to measure CD4+/CD8+ T cells and residual tumor cells 
(CD4−CD8−) in the culture (No Treatment, GD2.CAR, and CD19.CAR, representative of n 
= 6 donors per group). (D) Nude mice (Representative of No treatment n = 8, CD19.CAR 
and GD2.CAR n = 15 animals per group) were engrafted subretinally with the Y79-eGFP-
FFLuc tumor cell line. Seven days later mice were subretinal intra-tumor injected with 
GD2.CAR-Ts, or control CD19.CAR-Ts. Tumor growth within the eye was imaged and 
measured by in vivo bioluminescence by IVIS. Bioluminescence and imaging data can be 
found at figshare https://figshare.com/articles/IVIS1_tif/12485699. (E) BLI summary 
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(Quantification of the same cohort from panel D. Statistical significance was determined by 
two-way ANOVA with Bonferroni post hoc tests, (CD19.CAR versus GD2.CAR, Day 21) P 
= 0.0591, No Treatment n = 8, CD19.CAR, and GD2.CAR, n = 15 animals per group). Data 
presented in mean and SEM. (F) survival curves post treatment (No treatment n = 8, 
CD19.CAR, and GD2.CAR, n = 15 animals per group (Quantification of the same cohort 
from panel D and E). Statistical significance was determined by log-rank test (Two-sided), P 
= 0.005), and (G) tumor sizes measured (No Treatment n = 8, CD19.CAR, and GD2.CAR, n 
= 10 animals per group). The relevant source data are presented in figure 1.xlsx.
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Figure 2. GD2.CAR.15-Ts improve RB treatment but fail to achieve complete tumor eradication.
(A) Nude mice (CD19.CAR.15 and GD2.CAR.15, representative n = 15 animals per group) 
were engrafted intra-retina with Y79-GFP-FFLuc tumor cells. Seven days later mice were 
intra-tumor injected with GD2.CAR.15-Ts, or control CD19.CAR.15-Ts. Tumor growth 
within the eye was imaged and measured by in vivo bioluminescence by IVIS. 
Bioluminescence and imaging data can be found at figshare https://figshare.com/articles/
IVIS1_tif/12485699 (B) BLI summary (Quantification of the same cohort from panel A. 
Statistical significance was determined by two-way ANOVA with Bonferroni post hoc test 
(CD19.CAR.15 versus GD2.CAR.15, day 21) P = 0.0010, No Treatment n = 8, 
CD19.CAR.15 and GD2.CAR.15, n = 15 animals per group). Data presented in mean and 
SEM. (C) survival curves post treatment (Quantification of the same cohort from panel A 
and B. No Treatment n = 8, CD19.CAR.15 and GD2.CAR.15, n = 15 animals per group). 
Statistical significance was determined by log-rank test (Two-sided), P < 0.0001), and (D) 
tumor sizes (CD19.CAR.15 and GD2.CAR.15, n = 10 animals per group). (E) H&E paraffin 
histological section of a representative naïve eye, untreated Y79-GFP-FFLuc engrafted eye, 
and Y79-GFP-FFLuc engrafted eyes treated with GD2.CAR-Ts or GD2. CAR.15-Ts. 
Pictures are all taken 35 days post treatment (n =3 individual experiments). The relevant 
source data are presented in figure 2.xlsx.
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Figure 3. Injectable hydrogel further improved GD2.CAR.15-Ts treatment and prevent tumor 
recurrence
(A) Nude mice (Representative of hydrogel with CD19.CAR and CD19.CAR.15 n = 10 
animals per group, Hydrogel with GD2.CAR and GD2.CAR.15 n = 15 animals per group, 
Hydrogel only animal n = 7) were engrafted intra-retina with Y79-eGFP-FFLuc tumor cell 
line. Seven days later mice were intra-tumor injected with GD2.CAR-Ts, GD2.CAR.15-Ts, 
CD19.CAR-Ts or CD19.CAR.15-Ts encapsulated in chitosan-PEG hydrogel. 
Bioluminescence and imaging data can be found at figshare https://figshare.com/articles/
IVIS1_tif/12485699 (B) BLI summary (Quantification of the same cohort from panel A. 
Statistical significance was determined by two-way ANOVA with Bonferroni post hoc tests 
(CD19.CAR Hydrogel versus GD2.CAR Hydrogel, Day 21) P = 0.0024, (CD19.CAR.15 
Hydrogel versus GD2.CAR.15 Hydrogel, Day 21) P < 0.0001, Hydrogel with CD19.CAR 
and CD19.CAR.15 n = 10 animals per group, Hydrogel with GD2.CAR and GD2.CAR.15 n 
= 15 animals per group, Hydrogel only n = 7 animals per group). Data presented in mean 
and SEM. (C) survival curves post treatment (Quantification of the same cohort from panel 
A and B) No treatment n = 15, Hydrogel with CD19.CAR and CD19.CAR.15 n = 10 
animals per group, Hydrogel with GD2.CAR and GD2.CAR.15 n = 15 animals per group. 
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Statistical significance was determined by log-rank test (Two-sided), P <0.0001), and (D) 
tumor sizes (Hydrogel with CD19.CAR, GD2.CAR, CD19.CAR.15, and GD2.CAR.15, n = 
10 animals per group). (E) Representative H&E paraffin histological section of Y79-GFP-
FFLuc engrafted eyes treated with GD2.CAR-Ts or GD2.CAR.15-Ts encapsulated in 
hydrogels 35 days post CAR-Ts treatment (n =3 individual experiment). The relevant source 
data are presented in figure 3.xlsx.
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Figure 4. IL-15 and hydrogel prolong the lifespan of GD2.CAR-Ts in tumor
(A) FACS analysis of dissected eyes (Representative of no Treatment, GD2.CAR, 
GD2.CAR.15, hydrogel with GD2.CAR, and hydrogel with GD2.CAR.15, n = 3 eyes per 
group). T cells (CD45+ cells) and tumor cells (GD2+ cells) were measured. (B) Counts of 
tumor cells and T cells in the dissected eyes of the treated mice. (Quantification of the same 
cohort from panel A) GD2 was used as tumor marker and human CD45 was used to detect T 
cells, respectively. (No Treatment, GD2.CAR, GD2.CAR.15, hydrogel with GD2.CAR, and 
hydrogel with GD2.CAR.15, n = 3 independent experiments per group (C) H&E 
pathological analysis of the eye of naïve and tumor bearing mice receiving encapsulated 
GD2.CAR-Ts releasing IL-15 (representative of n =3 individual experiment). The relevant 
source data are presented in figure 4.xlsx.
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Figure 5. GD2.CAR.15-Ts and hydrogel treatment rescue mouse vision in the absence of toxicity 
to the retina
(A) Representative Fundus bright field, green fluorescence, and OCT images of naïve, 
untreated, or GD2.CAR.15-Ts and hydrogel treated nude mice engrafted with tumor cell 
lines 7 days and 21 days post-grafting (n = 5 eyes per group). (B) ERG scopotic a-wave, b-
wave, and photopotic b-wave of naïve, untreated, GD2CAR.15-Ts and hydrogel treated mice 
engrafted with tumor cell lines (Naïve, CD19.CAR.15, GD2.CAR.15, and Hydrogel with 
GD2.CAR.15, n = 7 eyes per group). Statistical significance was determined by one-way 
ANOVA with Tukey’s post hoc test (CD19.CAR.15 versus GD2.CAR.15 hydrogel P = 
0.009). Data presented as mean and SEM. The relevant source data are presented in figure 
5.xlsx.
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